Which finding indicates an adverse effect of fenofibrate?

A. Hyperglycemia: Fenofibrate primarily affects lipid metabolism and is not commonly associated with causing high blood glucose levels. While monitoring is important in clients with diabetes, hyperglycemia is not a typical adverse effect of this medication. B. Increased hemoglobin: Fenofibrate does not influence hemoglobin levels. Any changes in hemoglobin are unlikely to be related to fenofibrate therapy and should prompt evaluation for other underlying conditions. C. Hepatotoxicity: Fenofibrate can cause liver injury, evidenced by elevated liver enzymes or other signs of hepatotoxicity. Monitoring liver function tests before and during therapy is essential to detect adverse effects early and prevent serious liver complications. D. Fever: Fever is not a recognized adverse effect of fenofibrate. If a client develops fever, other causes such as infection or unrelated inflammatory processes should be investigated rather than attributing it to the medication.